Acción 6610 TWI BIOTECHNOLOGY, INC.
Añadir a una lista
Para utilizar esta función debe ser un cliente o miembro.
ConéctateRegístrate

Otros idiomas TWi Biotechnology, Inc.

Acciones

6610

TW0006610009

Precio de cierre Taipei Exchange
Otros sitios de cotización
 00:00:00 14/06/2024 		Varia. Cinco días. Varia. 1 de enero.
13 TWD +0,39 % Gráfico intradía de TWi Biotechnology, Inc. -1,52 % -7,14 %
09/04 TWi Biotechnology, Inc. presenta los resultados del ejercicio cerrado el 31 de diciembre de 2023 CI
2023 TWi Biotechnology, Inc. informa de los resultados del semestre finalizado el 30 de junio de 2023 CI

Otros idiomas

Buscar
Ver los resultados
Desbloquee todas las noticias: ¡Sea el primero en enterarse y reaccione antes que los mercados!
Inscripción 100% Gratuita
TWi Biotechnology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
TWi Biotechnology, Inc. Reports Earnings Results for the Half Year Ended June 30, 2023
TWi Biotechnology, Inc. Exploring Promising Treatment for Granuloma Annulare (Ga)
TWi Biotechnology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022
TWi Biotechnology, Inc. Reports Earnings Results for the Half Year Ended June 30, 2022
TWi Biotechnology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021
Twi Biotechnology, Inc. Reports Earnings Results for the Half Year Ended June 30, 2021
Winhealth Pharma and TWiB Enter into Strategic Licensing Partnership on AC-203
Twi Biotechnology, Inc. Reports Earnings Results for the Half Year Ended June 30, 2020
TWi Biotechnology Receives Canada Health Approval for AC-1101 Phase 1 CTA
Twi Biotechnology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2018
TWi Biotechnology, Inc. Announces Last Patient Enrolled in Phase 2 Study of AC-201CR for Treatment of Hemophilic Arthropathy
TWi Biotechnology, Inc. Announces Initiation of Phase 2 Proof-of-Concept Clinical Trial of AC-203 for Treatment of Inherited Epidermolysis Bullosa
TWi Biotechnology, Inc. Announces Regulatory Clearance to Begin Phase 2 Proof-of-Concept Clinical Trial of AC-203 for Treatment of Inherited Epidermolysis Bullosa
TWi Biotechnology Inc. Announces Last Patient Enrolled in Phase 2 Study of AC-201CR for Gout Treatment
TWi Biotechnology, Inc. Enters Development and Commercialization Agreement and Collaboration with Castle Creek Pharmaceuticals
TWi Biotechnology, Inc. Completes Multinational Phase II Dose-Ranging Study of AC-201
No hay resultados para esta búsqueda
Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Filtros

Buscar

Fecha de publicación

De

Hasta

  1. Bolsa de valores
  2. Acciones
  3. Acción 6610
  4. Noticias TWi Biotechnology, Inc.
  5. Otros idiomas